OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)GlobeNewsWire • 04/30/24
OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader eventProactive Investors • 04/09/24
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024GlobeNewsWire • 04/08/24
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryGlobeNewsWire • 04/02/24
OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptomsProactive Investors • 03/22/24
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101GlobeNewsWire • 03/22/24
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye diseaseProactive Investors • 03/21/24
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialGlobeNewsWire • 03/21/24
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventGlobeNewsWire • 03/20/24
OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trialProactive Investors • 02/09/24
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainGlobeNewsWire • 02/09/24
OKYO Pharma appoints leading ophthalmologists to its Scientific Advisory BoardProactive Investors • 01/31/24
OKYO Pharma reports 'statistical significance' achieved in Phase 2 trial of OK-101 in dry eye diseaseProactive Investors • 01/08/24
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024GlobeNewsWire • 01/05/24
OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visitProactive Investors • 12/04/23
OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal PainProactive Investors • 10/09/23
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)GlobeNewsWire • 10/09/23
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary SharesGlobeNewsWire • 09/15/23
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary SharesGlobeNewsWire • 09/14/23
OKYO Pharma completes enrollment in Phase 2 clinical trial to treat dry eye diseaseProactive Investors • 09/08/23